<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850417</url>
  </required_header>
  <id_info>
    <org_study_id>BA-SCAD</org_study_id>
    <nct_id>NCT04850417</nct_id>
  </id_info>
  <brief_title>Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection</brief_title>
  <acronym>BA-SCAD</acronym>
  <official_title>Randomized Clinical Trial Assessing the Value of Beta-Blockers and Antiplatelet Agents in Patients With Spontaneous Coronary Artery Dissection. (The BA-SCAD Randomized Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Hospital Universitario de la Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndrome (ACS).&#xD;
      Most patients are treated with beta-blockers (BB) and antiplatelet drugs (AP) on empiric&#xD;
      basis. The Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery&#xD;
      Dissection (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide,&#xD;
      prospective study developed under the auspices of the Spanish Society of Cardiology (SEC)&#xD;
      that aims to assess the efficacy of medical therapy in SCAD patients. Using a factorial 2x2&#xD;
      design, patients will be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1&#xD;
      month) vs prolonged dual AP therapy (DAPT) (12 months).Only patients with preserved left&#xD;
      ventricular ejection fraction (LVEF) will be randomized to BB (yes/no) because patients with&#xD;
      LVEF &lt;40% will receive BB according to current guidelines. Likewise, only medically managed&#xD;
      patients will be randomized to short AP therapy vs 1-year DAPT. The study will have a&#xD;
      pragmatic, open label, blind outcomes design (PROBE). A total of 600 SCAD patients will be&#xD;
      randomized within 2 years (300 per arm in a factorial 2x2 design). The primary efficacy&#xD;
      endpoint will include the composite of death, acute myocardial infarction (MI), stroke,&#xD;
      coronary revascularization, recurrent SCAD, and unplanned hospitalization for ACS or heart&#xD;
      failure at 1 year. The primary safety endpoint will be bleeding. All patients will be&#xD;
      clinically followed yearly. The main study will be pragmatic but a comprehensive set of&#xD;
      additional studies (clinical, imaging, biomarkers, inflammatory, immunologic, pharmacogenetic&#xD;
      and genetic) will be organized to ensure an holistic view on this challenging condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous coronary artery dissection (SCAD) is a relatively rare but important and&#xD;
      increasingly recognized cause of acute coronary syndrome (ACS). Most patients presenting with&#xD;
      SCAD are treated with beta-blockers (BB) and antiplatelet drugs (AP). Although appealing from&#xD;
      a pathophysiological standpoint, such management strategy is completely empiric. The&#xD;
      Beta-Blockers and Antiplatelet Agents in Patients with Spontaneous Coronary Artery Dissection&#xD;
      (BA-SCAD) randomized clinical trial is an academic, pragmatic, nation-wide, prospective study&#xD;
      developed under the auspices of the Spanish Society of Cardiology (SEC) that aims to assess&#xD;
      the efficacy of medical therapy in SCAD patients. Using a factorial 2x2 design, patients will&#xD;
      be randomized (1:1/1:1) to: 1) BB (yes/no) and 2) short AP regimen (1 month) vs prolonged&#xD;
      dual AP therapy (DAPT) (12 months). A conservative medical management will be initially&#xD;
      recommended, with coronary revascularization reserved for patients with ongoing/refractory&#xD;
      ischemia. Only patients with preserved left ventricular ejection fraction (LVEF) will be&#xD;
      randomized to BB (yes/no) because patients with LVEF &lt;40% will receive BB according to&#xD;
      current guidelines. Likewise, only medically managed patients will be randomized to short AP&#xD;
      therapy vs 1-year DAPT, because patients requiring coronary interventions will receive DAPT.&#xD;
      The study will have a pragmatic, open label, blind outcomes design (PROBE). The type and dose&#xD;
      of BB and AP agents will be at the discretion of the treating physician. Treatment adherence&#xD;
      will be reinforced and closely monitored and the potential influence of drug&#xD;
      discontinuation/cross-over on outcomes will be carefully evaluated. A total of 600 SCAD&#xD;
      patients will be randomized within 2 years (300 per arm in a factorial 2x2 design). The&#xD;
      primary efficacy endpoint will include the composite of death, acute myocardial infarction&#xD;
      (MI), stroke, coronary revascularization, recurrent SCAD, and unplanned hospital admission&#xD;
      for ACS or heart failure at 1 year. The primary safety endpoint will be bleeding according&#xD;
      the Bleeding Academic Research Consortium (BARC) criteria ≥ 3. An analysis of net clinical&#xD;
      benefit, including primary efficacy and safety endpoints, will also be performed. All&#xD;
      patients will be clinically followed at 1 year (primary endpoint) and yearly thereafter.&#xD;
      Although the main study will be pragmatic, following routine clinical practice, a systematic&#xD;
      and comprehensive set of additional ancillary studies and investigations (clinical, imaging,&#xD;
      biomarkers, inflammatory, immunologic, pharmacogenetic and genetic) will be prospectively&#xD;
      organized to ensure a multidisciplinary and holistic view on this challenging condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Factorial 2x2 design (a) beta-blockers yes/no; b) Antiplatelets short/long)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)</measure>
    <time_frame>1 year</time_frame>
    <description>MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE (death, myocardial infarction, coronary revascularization, stroke and heart failure)</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>MACE (death, myocardial infarction, coronary revascularization, stroke and heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (death, myocardial infarction, coronary revascularization)</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>MACE (death, myocardial infarction, coronary revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (death, myocardial infarction)</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>MACE (death, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)</measure>
    <time_frame>2, 3,4 and 5 years</time_frame>
    <description>MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Major Bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Major Bleeding (BARC &gt;=3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Bleeding (BARC &gt;=2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE and Bleeding</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>MACE (death, myocardial infarction, coronary revascularization, recurrent SCAD, stroke, unplanned admission for heart failure or acute coronary syndrome with dynamic ECG changes) and bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent SCAD</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Recurrent SCAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned admission for heart failure</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>Unplanned admission for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned admission for acute coronary syndrome with dynamic ECG changes</measure>
    <time_frame>1, 2, 3 years</time_frame>
    <description>Unplanned admission for acute coronary syndrome with dynamic ECG changes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substudy on strategies and results of coronary interventions</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Strategies and results of coronary interventions (different devices and modalities). Procedural success and angiographic results</description>
  </other_outcome>
  <other_outcome>
    <measure>Substudy on angiographic findings in relation to prognosis</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Angiographic analysis (visual and QCA, central corelab). Quantitative coronary angiography analyses (MLD, % diameter stenosis, TIMI Flow)</description>
  </other_outcome>
  <other_outcome>
    <measure>Substudy on value of intracoronary imaging in SCAD (OCT and IVUS)</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Intracoronary imaging in SCAD (central corelab) (OCT [optical coherence tomography] and IVUS [intravascular ultrasound] ). Minimal lumen area.</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-invasive imaging techniques</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Cardiac CT and CMR (coronary and peripheral arteries) (central corelab)</description>
  </other_outcome>
  <other_outcome>
    <measure>Substudy on inflammation and biomarkers</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Comprehensive analysis of biomarkers. Coordinating center (HULP). Including leucocytes, HsCRP, IL6</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenomic study</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Pharmacogenomic study. Coordinating center (HULP). Percent of responders to treatment according to the pharmacogenomic profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Micro RNAs and Genetic studies</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Micro RNAs and Genetic studies. Coordinating center (HULP). Array of different micro-RNAs</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Spontaneous Coronary Artery Dissection</condition>
  <arm_group>
    <arm_group_label>Beta-blockers and Short Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy&#xD;
(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta-blockers and Long Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy&#xD;
(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Beta-blockers and Short Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy&#xD;
(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Beta-blockers and Long Antiplatelet Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy&#xD;
(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker, aspirin, clopidogrel</intervention_name>
    <description>Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy</description>
    <arm_group_label>Beta-blockers and Long Antiplatelet Therapy</arm_group_label>
    <arm_group_label>Beta-blockers and Short Antiplatelet Therapy</arm_group_label>
    <arm_group_label>No Beta-blockers and Long Antiplatelet Therapy</arm_group_label>
    <arm_group_label>No Beta-blockers and Short Antiplatelet Therapy</arm_group_label>
    <other_name>Beta-blockers</other_name>
    <other_name>Aspirin</other_name>
    <other_name>Clopidogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Angiographic diagnosis of SCAD&#xD;
&#xD;
          -  Admission for ACS or other manifestations of ischemia&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock or severe hemoynamic instability&#xD;
&#xD;
          -  Concomitant severe heart disease requiring surgical correction (in &lt;2 years)&#xD;
&#xD;
          -  Medical condition seriously limiting life expectancy (&lt; 2 years)&#xD;
&#xD;
          -  Allergies or contraindication to drugs required in one of the study arms; the patient&#xD;
             may be randomized in the other arm (factorial design)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spanish Society of Cardiology Spanish Society of Cardiology</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Society of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Alfonso, MD</last_name>
    <phone>34 680483165</phone>
    <email>falf@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Spanish Society of Cardiology Spanish Society of Cardiology</last_name>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>Fernando Alfonso</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Spontaneous coronary artery dissection</keyword>
  <keyword>Beta-blockers</keyword>
  <keyword>Antiplatelets</keyword>
  <keyword>Coronary angiography</keyword>
  <keyword>Intracoronary imaging</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Coronary Vessel Anomalies</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To be decided by the steering committee upon formal official request by academic investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After the primary endpoint is reported</ipd_time_frame>
    <ipd_access_criteria>To be discussed</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

